AKB 9778

Drug Profile

AKB 9778

Alternative Names: AKB-9089; AKB-9778; AKB-9875; HPTP-beta mAb - Aerpio

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Procter & Gamble
  • Developer Aerpio Pharmaceuticals; Akebia Therapeutics; Duke University; Harvard Medical School; Johns Hopkins University School of Medicine; Massachusetts General Hospital; Massachusetts Institute of Technology; Max Planck Institute for Molecular Biomedicine; New York University
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors; TIE-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion
  • No development reported Age-related macular degeneration; Breast cancer

Most Recent Events

  • 11 Feb 2018 Aerpio Therapeutics completes enrolment in the TIME-2b trial for Diabetic retinopathy in USA (NCT03197870)
  • 06 Sep 2017 Active development is ongoing for Diabetic macular oedema (Adjunctive treatment, Monotherapy) in USA (NCT02050828)
  • 06 Sep 2017 AKB-9778 is still in phase II trials for Retinal vein occlusion (In adults, In the elderly) in USA (SC) (NCT02387788)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top